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Abstract
Purpose The REIC (reduced expression in immortalized
cells)/Dkk-3 is down-regulated in various cancers and con-
sidered to be a tumor suppressor gene. REIC/Dkk-3 mRNA
has two isoforms (type-a,b). REIC type-a mRNA has
shown to be a major transcript in various cancer cells, and
its promoter activity was much stronger than that of type-b.
In this study, we examined the methylation status of REIC/
Dkk-3 type-a in a broad range of human malignancies.
Methods We examined REIC/Dkk-3 type-a methylation
in breast cancers, non-small-cell lung cancers, gastric can-
cers, colorectal cancers, and malignant pleural mesothelio-
mas using a quantitative combined bisulWte restriction
analysis assay and bisulfate sequencing. REIC/Dkk-3 type-a
and type-b expression was examined using reverse tran-
scriptional PCR. The relationships between the methylation
and clinicopathological factors were analyzed.
Results The rate of REIC/Dkk-3 type-a methylation
ranged from 26.2 to 50.0% in the various primary tumors
that were examined. REIC/Dkk-3 type-a methylation in
breast cancer cells was signiWcantly heavier than that in the
other cell lines that we tested. REIC/Dkk-3 type-a methyla-
tion was inversely correlated with REIC/Dkk-3 type-a
expression. There was a correlation between REIC/Dkk-3
type-a and type-b mRNA expression. REIC/Dkk-3 type-a
expression was restored in MDA-MB-231 cells using
5-aza-2-deoxycytidine treatment. We found that estrogen
receptor–positive breast cancers were signiWcantly more
common among the methylated group than among the non-
methylated group.
Conclusions REIC/Dkk-3 type-a methylation was fre-
quently detected in a broad range of cancers and appeared
to play a key role in silencing REIC/Dkk-3 type-a expres-
sion in these malignancies.
Keywords DNA methylation · REIC/Dkk-3 · 
Breast cancer · Lung cancer · Mesothelioma
Introduction
Accumulating evidence suggests that tumor progression is
governed not only by genetic changes intrinsic to cancer
cells but also by epigenetic changes. In cancer epigenetics,
aberrant CpG methylation in the promoter region is a key
mechanism for gene inactivation, resulting in tumorigenesis
in human malignancies (Toyooka and Shimizu 2004).
The REIC (reduced expression in immortalized cells)/
Dkk-3(Dickkopf-3) cDNA, which was expressed in human
normal cells and was down-regulated in human immortal-
ized cells and human tumor-derived cells, was identiWed
using a representative diVerence analysis system (Tsuji
et al.  2000). The amino acid sequence revealed that the
REIC gene product was human Dkk-3, one of the Dkk fam-
ily members. The Dkk family of secreted proteins consists
T. Hayashi · H. Asano · S. Toyooka (&) · K. Tsukuda · J. Soh · 
T. Shien · N. Taira · Y. Maki · N. Tanaka · H. Doihara · S. Miyoshi
Department of Cancer and Thoracic Surgery, 
Graduate School of Medicine, Dentistry and Pharmaceutical 
Sciences, Okayama University, 2-5-1 Shikata-cho, 
Okayama 700-8558, Japan
e-mail: toyooka@md.okayama-u.ac.jp
Y. Nasu
Department of Urology, Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, Okayama University, 
Okayama, Japan
N. Huh
Department of Cell Biology, Graduate School of Medicine, 
Dentistry and Pharmaceutical Sciences, 
Okayama University, Okayama, Japan800 J Cancer Res Clin Oncol (2012) 138:799–809
123
of four members, which share two conserved cysteine-rich
domains (Glinka et al. 1998; Krupnik et al. 1999). Dkk-1,
the best-characterized member of the Dkk family, functions
as a Wnt antagonist or agonist by binding to and inhibiting
or activating the Wnt coreceptor LRP6 (BaWco et al. 2001).
Unlike Dkk-1, Dkk-2, and Dkk-4, however, REIC/Dkk-3
was recently shown to inhibit TCF-4 receptor activity in
lung cancer cells (Yue et al. 2008). TCF-4 activates c-Myc
and cyclin D1 through the Wnt/beta-catenin pathway and
promotes tumor invasion and metastasis. Because REIC/
Dkk-3 is down-regulated in a variety of malignancies and
the overexpression of REIC/Dkk-3 suppresses cell growth,
REIC/Dkk-3 has been proposed to act as a tumor suppressor
(Tsuji et al. 2001; Kurose et al. 2004). Hypermethylation
and the down-regulation of REIC/Dkk-3 were observed in a
variety of malignancies including non-small-cell lung can-
cers (NSCLCs) (Kobayashi et al. 2002; Licchesi et al.
2008), gastrointestinal cancers (Maehata et al. 2008), renal
clear cell carcinoma (Kurose et al. 2004), acute lympho-
blastic leukemia (Roman-Gomez et al. 2004) and osteosar-
comas (Hoang et al. 2004). We previously showed
the therapeutic eVect of REIC/Dkk-3 in prostate cancers
(Abarzua et al. 2005; Edamura et al. 2007) and malignant
pleural mesothelioma (MPM) (Kashiwakura et al. 2008). In
addition, tumor suppression by REIC/Dkk-3 has also been
conWrmed in other malignant tumors (Hsieh et al. 2004;
Hoang et al. 2004).
REIC/Dkk-3 mRNA has two isoforms (type-a,b; Gen-
Bank accession AB057804). Many papers have described
the methylation status in the promoter of REIC/Dkk-3 type-b
(Licchesi et al. 2008; Maehata et al. 2008; Veeck et al.
2009). However, the promoter of REIC/Dkk-3 type-a also
seems to be important, since Kobayashi et al. (2002) (the
group that Wrst identiWed the REIC/Dkk-3 in immortalized
cells) have demonstrated that the promoter activity of
REIC/Dkk-3 type-a (major promoter) had an approximately
26-fold stronger eVect than that of REIC/Dkk-3 type-b
(minor promoter) in a luciferase assay, and the major tran-
script was REIC/Dkk-3 type-a in various cancer cells they
tested. They suggested that hypermethylation of the major
promoter (type-a) was a major mechanism for the down-
regulation of REIC expression. They also suggested that the
methylation of the minor promoter (type-b) was accompa-
nied with that of major promoter (type-a) in most cases
except four lung cancer cells that they tested. Regardless,
those four lung cancer cells had type-b hypermethylation,
REIC/Dkk-3 type-b expression was detected in those four
lung cancer cells. So they discussed the possibility that
minor promoter (type-b) was utilized for the expression in a
tissue-speciWc manner, as seen in dual promoter of APC
gene.
In this study, we examined the DNA methylation of
REIC/Dkk-3 type-a in various kinds of cancers by quantita-
tive combined bisulWte restriction analysis (qCOBRA) and
investigated the correlation between the REIC/Dkk-3 type-a
methylation and REIC/Dkk-3 type-a expression. The qCO-
BRA assay can provide more reliable results because
the conventional methylation-sensitive restriction enzyme
assay that Kobayashi et al. (2002) performed was recently
known to be prone to false-positive results due to spurious
incomplete digestion (Xiong and Laird 1997). We also ana-
lyzed the correlation between REIC/Dkk-3 type-a and type-
b expression in various cancer cell lines. Furthermore, we
examined the correlation between REIC/Dkk-3 type-a
methylation and the clinicopathological features of primary
tumors.
Materials and methods
Clinical samples and cell culture
Surgically resected specimens of 37 primary breast cancers,
42 primary NSCLCs, 21 primary gastric cancers, 20 pri-
mary colon cancers, and 7 MPMs were obtained from Oka-
yama University Hospital (Okayama, Japan), 6 MPMs were
obtained from Okayama Rousai Hospital (Okayama,
Japan), 5 MPMs were obtained from National Sanyo
Hospital (Yamaguchi, Japan), and 27 MPMs were obtained
from Karmanos Cancer Center (MI). Ten corresponding
non-malignant breast tissues and 10 non-malignant lung tis-
sues were also examined. All tissues were frozen with the
liquid nitrogen immediately after surgery and were stored
at  ¡80°C until extraction of DNA. Institutional Review
Board permission and informed consent were obtained for
all cases.
Seven breast cancer cell lines (HCC70, HCC1599,
HCC1806, MDA-MB-231, MDA-MB-361, MCF7, and
ZR75-1), 11 lung cancer cell lines (NCI-H23, NCI-H44,
NCI-H125, NCI-H157, NCI-H1299, NCI-H1819, NCI-
H1963, NCI-H1975, NCI-H2009, NCI-H358, and A549),
4 MPM cell lines (NCI-H2052, NCI-H2373, NCI-H2452,
and NCI-H290), and 6 prostate cancer cell lines (PC3,
LNCap-FGC, Du145, Caki-1, Caki-2, and KPK) were
examined in this study. MCF7, ZR-75-1, MDA-MB-231,
and MDA-MB-361 were obtained from Cell Resource
Center for Biomedical Research Institute of Development
Aging and Cancer Tohoku University (Miyagi, Japan).
Seven cell lines (HCC70, HCC1599, HCC1806, H2052,
H2373, H290, and H2452) were kind gifts from Adi F.
Gazdar (Department of Pathology, University of Texas
Southwestern Medical Center, Dallas, TX). Six cell lines
(PC3, LNCap-FGC, Du145, Caki-1, Caki-2, and KPK) were
kind gifts from the department of urology (Okayama Univer-
sity, Okayama, Japan). The other cell lines were obtained from
American Type Culture Collection (Manassas, VA). The cellsJ Cancer Res Clin Oncol (2012) 138:799–809 801
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were maintained in RPMI-1640 medium (Sigma Chemical
Co., Saint Louis, MO) supplemented with 10% FBS and
were incubated in 5% CO2.
DNA extraction and DNA methylation modiWcation
Genomic DNA was extracted from the surgically resected
frozen samples and cultured cells by digestion with SDS/
proteinase K followed by phenol/chloroform (1:1) extrac-
tion and ethanol precipitation. Two micrograms of each
DNA was treated with EZ DNA Methylation Kit (ZYMO
RESEARCH, Orange, CA), following the manufacturer’s
instructions, and was stored at ¡20°C until use.
Quantitative COBRA assay
Nested PCR was carried out using bisulWte-treated DNA fol-
lowed by the restriction enzyme digestion. First-round touch-
down PCR was performed under the following conditions:
95°C for 12 min, 40 cycles of 94°C for 45 s, annealing temper-
ature between 58 and 56°C for 1 min, 72°C for 3 min,
followed by Wnal extension step at 72°C for 7 min in a 25-l
reaction mixture containing 67 mM Tris–HCl (pH 8.8),
16.6 mM (NH4)2SO4, 6.7 mm MgCl2, 10 mM -mercap-
toethanol, 1.25 mM of each deoxynucleotide triphosphate
(dNTP) mixture, 0.5 M of each primer, 0.5 unit of HotStar
Taq DNA Polymerase (Qiagen, Valencia, CA), and 100 ng
of bisulWte-treated DNA. Second-round touchdown PCR
was performed using 0.4 l of the Wrst-round PCR products
as a template under same condition, but 47 cycles. Univer-
sal methylated DNA and universal unmethylated DNA
were used for positive control and negative control, respec-
tively. The location of the CpG dinucleotides in the exon1
and in the 5-Xanking region of REIC/Dkk-3 is shown in
Fig. 1. Primers were designed using Primer Express soft-
ware ver.1.0 in the promoter region of REIC/Dkk-3 type-a.
Primers for the Wrst-round PCR were REIC-COBRA-F1 5-T
GGGTTGTTGTAAGTTTGAAGGT-3 and REIC-COBRA-
R1 5-CTCACCCACCCCRACTAAAC-3. Primers for the
second-round PCR were as follows: REIC-COBRA-F2 5-T
GAAGGTTAGATAAGAYGGGTTTAGG-3 and REIC-
COBRA-R2 5-ACCCACCCCRACTAAACCRAAT-3.
These primers were designed to ensure ampliWcation of
both methylated and unmethylated forms. Two microliters
of second PCR products were digested with 3 units of
BstUI (whose restriction site is CGCG) for the restriction
fragment length polymorphism analysis. The amplicon of
second PCR was named RRCOBRA (Region for REIC-
COBRA), and the 5 restriction sites of BstUI are shown in
Fig. 1. The digested PCR products were visualized on 3%
agarose gels stained with ethidium bromide. The percent-
ages of digested band were analyzed by NIH ImageJ 1.37 V
software (http://rsb.info.nih.gov/ij) as described previously
(Xiong and Laird 1997). We performed linear regression
analysis of qCOBRA with nested PCR using serial dilution
to examine whether qCOBRA with nested PCR really
reXected % methylation. We diluted unmethylated DNA
amplicon with methylated amplicon to make serial dilution
(% methylated DNA; 0, 10, 20, 30, 50, 70, 80, 90, 100%)
and performed qCOBRA, as described above.
BisulWted DNA sequencing analysis
RRCOBRA was cloned into pCR2.1-TOPO Vector using
TOPO TA cloning kit (Invitrogen Life Technologies, Carls-
bad, CA) following manufacturer’s instructions. To deter-
mine the methylation status in the promoter lesion of REIC/
Dkk-3 gene, Wve breast cancer cell lines (MCF-7, MDA-
MB-231, ZR75-1, HCC1806, and HCC1599) and a lung
cancer cell line (H1299) were examined. Seven individual
clones from each cell line were sequenced using the dGTP
BigDye terminator v3.1 Cycle Sequencing Kit with the
ABI PRISM 3100 Genetic Analyzer (Applied Biosystems,
Foster City, CA).
RNA extraction and reverse transcriptional (RT)-PCR
Total RNA was extracted from cultured cells using RNeasy
Mini Kit (Qiagen, Valencia, CA) following the manufac-
turer’s instruction. Oligo(dT)-primed cDNA was synthe-
sized using Super-Script II (Qiagen, Valencia, CA) with
DNase treatment. RT-PCR was carried out in 20 l of reac-
tion mixture with 1xPCR buVer, 200 M of dNTP, 0.3 M
of each primer, 0.5 units of HotStarTag DNA Polymerase,
and 100 ng of cDNA. A touchdown PCR was performed
for REIC/Dkk-3 type-a and type-b under the following con-
ditions: 95°C for 12 min, 35 cycles of 94°C for 30 s,
annealing temperature between 62 and 58°C for 1 min,
72°C for 3 min, followed by Wnal extension step at 72°C for
7 min. As an internal control, RT-PCR for GAPDH was
carried out under the following conditions: 95°C for
12 min, 35 cycles of 94°C for 45 s, 55°C for 90 s, 72°C for
90 s, followed by Wnal extension step at 72°C for 7 min.
The primers for REIC/Dkk-3 type-a expression were
REIC (a)-F 5-GGGAGCGAGCAGATCCAGT-3 (exon1a)
and REIC(a)-R 5-TTTGTCCAGTCTGGTTGTTGGT-3
(exon3). The primers for REIC/Dkk-3 type-b expression were
REIC(b)-F 5-TGGGAGCTATTAGCGTAGAGGA T-3
(exon1b) and REIC(b)-R 5-CATTGTGATAGCTGG
GAGGTAAG-3 (exon3). The PCR products were visual-
ized on 2% agarose gels stained with ethidium bromide.
The bands were analyzed using NIH ImageJ 1.37 V soft-
ware. The expression ratio in each cell line was deWned as
the ratio of particular sample when compared to those of
H1299. To conWrm the responsibility of DNA methylation
for REIC/Dkk-3 silencing, we treated heavily methylated802 J Cancer Res Clin Oncol (2012) 138:799–809
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cell lines (MDA-MB-231) with 5-aza-2-deoxycytidine
(5-Aza-CdR) at the concentration of 5 and 8 M for 6 days
with medium changes on days 1, 3, and 5. Treated and
untreated cells from individual triplicate Xasks were har-
vested on day 6 to determine the REIC/Dkk-3 type-a
expression using RT-PCR.
ER, PgR, and HER2 status in primary breast cancers
Estrogen receptor (ER), progesterone receptor (PgR), and
HER2 status in primary breast cancers were obtained from
patient medical records. HER2 positive was deWned as a
score of 2+ and 3+ by immunohistochemistry.
Statistical analyses
The frequencies of REIC/Dkk-3 methylation between two
groups were compared using the Fisher’s exact test or
Mann–Whitney’s  U test when appropriate. Probability
value less than 0.05 was deWned as being statistically sig-
niWcant. All data were analyzed by JMP9 for Windows
(SAS Institute, Cary, NC).
Results
DNA methylation status in the promoter region 
of REIC/Dkk-3 type-a
The results of bisulWte genomic DNA sequencing of
RRCOBRA are shown in Fig. 1. Each CpG in the 5-Xank-
ing region and in exon1a was heavily methylated in MCF7,
MDA-MB-231, and ZR75-1. The CpGs in the 5-Xanking
region of exon1a were lightly to moderately methylated,
but the CpGs in exon1a were rarely methylated in
HCC1806 and HCC1599. In contrast, most of the CpGs
were rarely methylated in H1299.
We performed the linear regression analysis using the
nested qCOBRA and conWrmed the quantitative capacity
(data not shown). Representative examples of the COBRA
assay in breast cancer cell lines are shown in Fig. 2a. The
percentages of REIC/Dkk-3 type-a methylation were calcu-
lated by qCOBRA in each cell line and primary tumor
(Fig. 2b, c, respectively) and summarized in Table 1. We
decided the samples with more than 10% of digested bands
as methylation positive in this study. Aberrant methylation
was detected in 7 of the 7 (100%) breast cancer cell lines,
16 of the 37 (43.2%) primary breast cancers, 5 of the 11
(45.4%) lung cancer cell lines, 11 of the 42 (26.2%) pri-
mary lung cancers, 0 of 4 (0%) MPM cell lines, 7 of the 27
(25.9%) USA primary MPMs, 7 of the 18 (38.9%) Japanese
primary MPMs, 8 of the 21 (38.1%) primary gastric can-
cers, and 10 of the 20 (50.0%) primary colon cancers.
REIC/Dkk-3 methylation was not detected in 10 normal
breast tissues and 10 normal lung tissues (data not shown).
The methylation of REIC/Dkk-3 type-a in the breast cancer
cell lines was more frequent than that in the lung, MPM,
and prostate cancer cell lines (p =0 . 0 2 ,  p =0 . 0 1 ,  a n d
p = 0.04, respectively). However, no signiWcant diVerences
in methylation were observed among the primary breast,
lung, MPMs, gastric, and colon cancers (Fig. 2c). The
results of qCOBRA in Wve breast cancer cell lines and a
lung cancer cell line (H1299) corresponded with the results
of bisulWte sequencing.
REIC/Dkk-3 mRNA expression in cell lines and correlation 
with qCOBRA assay
Representative example of RT-PCR for REIC/Dkk-3 type-a
and type-b in the breast cancer cell lines was shown in
Fig. 2d. Expression of REIC/Dkk-3 type-a was only
detected in HCC1599 and HCC1806 cells, which rarely to
moderately harbored REIC/Dkk-3 methylation. Expression
of REIC/Dkk-3 type-b was also detected in HCC1599 and
HCC1806 cells. The results of expression of REIC/Dkk-3
type-a and type-b in all cell lines (n = 28) were summarized
in Table 2. There was a correlation between the expression
of REIC/Dkk-3 type-a and type-b (p < 0.01). The relative
expressions of REIC/Dkk-3 type-a mRNA and the percent-
ages of REIC/Dkk-3 type-a methylation are shown in Fig. 3.
The expression of REIC/Dkk-3 type-a and REIC/Dkk-3
type-a methylation was inversely correlated in the cell lines
that were examined (p < 0.01). To conWrm that methylation
was responsible for the gene silencing, heavily methylated
MDA-MB-231 cells were treated with 5-Aza-CdR. REIC/
Dkk-3 type-a mRNA expression was restored by the treat-
ment of 5-Aza-CdR in a dose-dependent manner (Fig. 4).
REIC/Dkk-3 methylation and clinicopathological 
correlation
We next examined the relationships between the REIC/
Dkk-3 methylation status and the clinicopathological
Fig. 1 Map of the 5-Xanking region of REIC/Dkk-3 and the bisulWte
genomic DNA sequence. Upper  Wgure demonstrates the promoter
region of REIC/Dkk-3. Gray bars indicate exons, and the bent arrow
indicates the transcription start site (TSS) (+1). Thin vertical lines on the
horizontal line indicate the sites of CpG dinucleotides. Arrow heads
indicate the restriction sites of BstUI. COBRA primer sets are indicated
by pairs of bold arrows. Dark gray bar under the COBRA primer sets
indicates RRCOBRA. Methylation status of individual subcloned DNA
fragments of each cell line is shown below. Each circle represents a
CpG dinucleotide in 5-Xanking region of REIC/Dkk-3 (for ¡213 to
+205 nt). The numbers at the top indicate the CpG dinucleotide in the
RRCOBRA (from 5 to 3). These numbers correspond to those depict-
ed in upper Wgures. Open circle represents non-methylated CpG dinu-
cleotide. Black circle represents methylated CpG dinucleotide
804 J Cancer Res Clin Oncol (2012) 138:799–809
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Fig. 2 Quantitative COBRA assay. The results of COBRA assay for
REIC/Dkk-3 type-a in breast cancer cell lines were shown in
a. Methylated alleles were fragmented with restriction enzyme modiW-
cation, and unmethylated alleles were uncut. Percentages of digested
band in cell lines (b) and primary tumors (c) were quantitated by NIH
ImageJ 1.37 V software. The horizontal bars indicate the average in
each group. The mRNA expression of REIC/Dkk-3 type-a and type-b
in breast cancer cell lines was shown in d. PC universal methylated
DNA as positive control; NC universal unmethylated DNA as negative
control
a
H
C
C
7
0
H
C
C
1
5
9
9
H
C
C
1
8
0
6
M
D
A
-
M
B
-
2
3
1
M
D
A
-
M
B
-
3
6
1
M
C
F
7
Z
R
7
5
-
1
N
C
P
C
418 bp
c b
%
 
M
e
t
h
y
l
a
t
i
o
n
 
(
q
C
O
B
R
A
)
B
r
e
a
s
t
 
c
a
n
c
e
r
c
e
l
l
 
l
i
n
e
s
 
(
n
=
7
)
P
r
o
s
t
a
t
e
 
c
a
n
c
e
r
c
e
l
l
 
l
i
n
e
s
 
(
n
=
6
)
M
e
s
o
t
h
e
l
i
o
m
a
c
e
l
l
 
l
i
n
e
s
 
(
n
=
4
)
L
u
n
g
 
c
a
n
c
e
r
c
e
l
l
 
l
i
n
e
s
(
n
=
1
1
)
P=0.02
P=0.01
40
60
80
100
(%)
20
0
P=0.04
40
60
80
100
(%)
B
r
e
a
s
t
 
c
a
n
c
e
r
s
(
n
=
3
7
)
G
a
s
t
r
i
c
 
c
a
n
c
e
r
s
(
n
=
2
1
)
M
e
s
o
t
h
e
l
i
o
m
a
s
(
U
S
A
,
 
n
=
2
7
)
L
u
n
g
 
c
a
n
c
e
r
s
(
n
=
4
2
)
M
e
s
o
t
h
e
l
i
o
m
a
s
(
J
a
p
a
n
,
 
n
=
1
8
)
C
o
l
o
n
 
c
a
n
c
e
r
s
(
n
=
2
0
)
%
 
M
e
t
h
y
l
a
t
i
o
n
 
(
q
C
O
B
R
A
)
20
0
d
GAPDH
REIC/Dkk-3 
type-a mRNA
H
C
C
7
0
H
C
C
1
5
9
9
H
C
C
1
8
0
6
M
D
A
-
M
B
-
2
3
1
M
D
A
-
M
B
-
3
6
1
M
C
F
7
Z
R
7
5
-
1
452 bp
REIC/Dkk-3 
type-b mRNA
377 bpJ Cancer Res Clin Oncol (2012) 138:799–809 805
123
factors described in Table 3. For the breast cancers, we
observed that ER-positive cases were more common in the
methylated group than in the non-methylated group
(p = 0.03). No signiWcant relationships between REIC/Dkk-
3 methylation and the other clinicopathological factors
were observed.
Discussion
In this study, we demonstrated that arbitrary CpG methyla-
tion in REIC/Dkk-3 type-a promoter region was frequently
observed in solid malignancies. Regarding qCOBRA in this
study, we conWrmed the accuracy of this assay by linear
regression analysis because we performed nested PCR. We
decided the samples with more than 10% of digested bands
as methylation positive to maintain compatibility with con-
ventional COBRA assay, as we could distinguish 10% of
digested band on the agarose gel electrophoresis. Colella
et al. (2003) also used a 10% threshold to declare methyla-
tion when qCOBRA was compared with pyrosequencing
methylation analysis. So a 10% threshold seems to be rea-
sonable criteria to distinguish methylation positive. We
examined cell lines using qCOBRA assay, and the accuracy
of the qCOBRA was also conWrmed by bisulfate genomic
DNA sequencing and linear regression analysis.
The REIC/Dkk-3 type-a methylation, which was deter-
mined using qCOBRA assay, revealed to be inversely cor-
related with the REIC/Dkk-3 type-a mRNA expression
among the cell lines (p < 0.01), and the restoration of REIC/
Dkk-3 type-a expression by 5-Aza-CdR treatment was
observed in a REIC/Dkk-3 type-a methylated cell line.
These results indicate that DNA methylation of REIC/Dkk-
3 type-a was responsible for silencing REIC/Dkk-3 type-a
expression. As reported previously, we conWrmed that there
was a correlation between REIC/Dkk-3 type-a expression
and type-b expression in the cell lines that we examined
(p < 0.01). Discrepancy of the expression level between
REIC/Dkk-3 type-a and type-b was observed in lung cancer
cell lines, although the expression of REIC/Dkk-3 type-a
completely corresponded with the expression of REIC/Dkk-
3 type-b in other cell lines, indicating that REIC/Dkk-3
type-b might be utilized for the expression in a tissue-speciWc
manner, as Kobayashi et al. (2002) described.
Among the cancers that were examined, REIC/Dkk-3
type-a methylation was more frequently detected in breast
cancer cell lines, although moderate methylation was also
observed in other cancers. A previous report showed that
the introduction of REIC/Dkk-3 into some breast cancer
Table 1 Rate of REIC/Dkk3 methylation in each human cancer by
quantitative COBRA assay
ND not determined
Organ Number of REIC/Dkk3 methylated sample (%)
Cell lines Primary tumors
Breast cancer 7 of 7 (100%) 16 of 37 (43.2%)
Lung cancer 5 of 11 (45.4%) 11 of 42 (26.2%)
Malignant pleural mesothelioma
USA 0 of 4 (0%) 7 of 27 (25.9%)
Japanese ND 7 of 18 (38.9%)
Gastric cancer ND 8 of 21 (38.1%)
Colon cancer ND 10 of 20 (50.0%)
Prostate cancer 3 of 6 (50%) ND
Table 2 Expression of REIC/Dkk-3 type-a and type-b in various can-
cer cells
Organ mRNA expression
Type-a Type-b
Breast cancers
HCC70 ¡¡
HCC1599 + +
HCC1806 + +
MDA-MB-231 ¡¡
MDA-MB-361 ¡¡
MCF7 ¡¡
ZR75-1 ¡¡
Lung cancers
H23 + ¡
H44 ¡¡
H125 + ¡
H157 + +
H1299 + +
H1819 + +
H1963 + +
H1975 ¡ +
H2009 ¡¡
H358 ¡¡
A549 + +
MPMs
H2052 + +
H2373 + +
H2452 ¡¡
H290 + +
Prostate cancers
Caki-1 + +
Caki-2 + +
Du145 + +
KPK + +
LNCap-FGC ¡¡
PC3 ¡¡806 J Cancer Res Clin Oncol (2012) 138:799–809
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cells had an antitumor eVect (Kawasaki et al. 2009). In
addition, the introduction of REIC/Dkk-3 into cancer cells
had a direct eVect on the induction of apoptosis and an indi-
rect eVect on the activation of tumor immunity in NK cells
through the up-regulation of IL-7 (Sakaguchi et al. 2009).
Furthermore, REIC/Dkk-3 induces the diVerentiation of
human CD14+ monocytes into a novel cell type, resembling
immature dendritic cells generated with IL-4 and GM-CSF
(Watanabe et al. 2009). These Wndings support the possible
utility of REIC/Dkk-3 gene therapy for not only breast can-
cers but also a broad range of human malignancies. Indeed,
REIC/Dkk-3 gene therapy is ongoing for prostate cancer
(http://clinicaltrials.gov/ct2/show/NCT01197209).
Regarding the clinicopathological factors, we found
that ER-positive breast cancer was more common in the
methylated group than in the non-methylated group in the
present study. In contrast, Veeck et al. (2009) reported
that there was no correlation between REIC/Dkk-3 meth-
ylation and ER and PgR statuses. In other cancers, no sig-
niWcant relationship was observed between the REIC/Dkk-3
methylation status and any of the clinicopathological fac-
tors that were examined. Previous study has shown that
REIC/Dkk-3 methylation was associated with poor sur-
vival in primary breast cancers (Veeck et al. 2009). We
could not compare these results directly because they
examined the REIC/Dkk-3 type-b methylation, which has
a lower promoter activity than that of REIC/Dkk-3 type-a.
In addition, the number of cases in this study may have
been too small for the survival analysis, since the primary
purpose of this study was to detect REIC/Dkk-3 type-a
methylation and to examine the correlation between meth-
ylation and expression. In lung cancer, reduced expres-
sion of REIC/Dkk-3 was previously shown to be frequent
in poorly diVerentiated adenocarcinoma and squamous
cell carcinoma (Nozaki et al. 2001). Further investiga-
tions are needed to determine the clinicopathological
impact of REIC/Dkk-3 type-a methylation.
In conclusion, we found that the promoter region of REIC/
Dkk-3 type-a was frequently methylated in breast, lung, gas-
tric, colon, and prostate cancers and MPMs. REIC/Dkk-3
type-a methylation and REIC/Dkk-3 type-a mRNA expres-
sion were inversely correlated in the cell lines that were
examined. Our results suggest that REIC/Dkk-3 type-a meth-
ylation is an important mechanism in the pathogenesis of
various types of malignancies. Since gene therapy using
Fig. 3 Relative expression of REIC/Dkk-3 type-a mRNA and per-
centages of REIC/Dkk-3 methylation in each cell line. Columns show
the relative expression of REIC/Dkk-3 type-a mRNA in each sample.
The expression ratio was deWned as the ratio of particular sample when
compared to those of H1299. % methylation was calculated by qCO-
BRA assay
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Table 3 Clinicopathological factors and REIC/Dkk-3 methylation in
various primary cancers
Variables Number of 
methylation-positive 
samples (%)
Total (n = 38) 16 (39)
A. Primary breast cancers
Age
<65 (n = 32) 14 (44)
¸65 (n =6 ) 1  ( 1 7 )
Histology
Papillotubular (n =8 ) 2  ( 2 5 )
Solid-tubular (n = 11) 4 (36)
Scirrhous (n = 17) 9 (53)
Others (n =2 ) 0
T categories
1 (n = 11) 6 (55)
2 (n = 16) 5 (31)
3 (n =3 ) 1  ( 3 3 )
4 (n =8 ) 3  ( 3 8 )
N categories
0 (n = 15) 6 (40)
1 (n = 23) 9 (39)
M categories
0 (n = 36) 14 (23)
1 (n =2 ) 1  ( 5 0 )
Stage
I (n =9 ) 5  ( 5 6 )
II (n = 15) 5 (33)
III (n = 12) 4 (33)
IV (n =2 ) 1  ( 5 0 )
Estrogen receptor*
Positive (n = 19) 11 (58)
Negative (n = 18) 4 (22)
Progesterone receptor
Positive (n = 18) 9 (50)
Negative (n = 15) 6 (40)
HER2 status
Positive (n = 11) 3 (27)
Negative (n = 19) 10 (53)
Total (n = 41) 11 (27)
B. Primary lung cancers
Age
<65 (n = 17) 3 (18)
¸65 (n = 24) 8 (33)
Histology
Adenocarcinoma (n = 27) 7 (26)
Squamous cell carcinoma (n = 14) 4 (29)
Table 3 continued
Total (n = 41) 11 (27)
T categories
1 (n = 27) 7 (26)
2 (n = 12) 4 (33)
3 (n =0 ) 0
4 (n =2 ) 0
N categories
0 (n = 29) 8 (28)
1 (n = 10) 2 (20)
M categories
0 (n = 39) 11 (28)
1 (n =2 ) 0
Stage
I (n = 28) 8 (29)
II (n =4 ) 1  ( 2 5 )
III (n =7 ) 1  ( 1 4 )
IV (n =2 ) 0
Total (n = 21) 8 (38)
C. Primary gastric cancers
Age
<65 (n = 10) 5 (50)
65· (n = 11) 3 (27)
Histology
Intestinal (n = 10) 5 (50)
DiVuse (n = 11) 3 (27)
T categories
1 (n =3 ) 1  ( 5 5 )
2 (n =8 ) 4  ( 5 0 )
3 (n =7 ) 2  ( 2 9 )
4 (n =3 ) 0
N categories
0 (n =7 ) 4  ( 5 7 )
1 · (n = 14) 4 (29)
Stage
I (n =6 ) 4  ( 6 7 )
II (n =3 ) 1  ( 3 3 )
III (n =5 ) 3  ( 6 0 )
IV (n =7 ) 0
Total (n = 20) 10 (50)
D. Primary colon cancers
Age
<65 (n =9 ) 5  ( 5 6 )
65· (n = 11) 5 (46)808 J Cancer Res Clin Oncol (2012) 138:799–809
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REIC/Dkk-3 expressing adenovirus vectors is currently ongo-
ing for the treatment of prostate cancer, similar therapeutic
modalities may be applicable for other types of cancers.
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